CureMetrix
CureMetrix develops FDA-cleared AI software for mammography analysis, detecting breast arterial calcifications and cardiovascular risk on routine screening mammograms for healthcare providers and imaging centers, deployed at 400+ clinical sites.
- Company typePrivate
- Founded2014
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What CureMetrix does
CureMetrix, Inc. is a San Diego-based medical technology company founded in 2014 that develops FDA-cleared AI-powered software as a medical device (SaMD) for mammography analysis. The company's product suite centers on detecting and localizing Breast Arterial Calcifications (BAC) on routine screening mammograms — converting standard breast cancer screening exams into dual-purpose tools that simultaneously flag cardiovascular risk without additional radiation or procedures. Its flagship product, cmAngio (510(k) K250754, cleared October 2023), is the first FDA-cleared AI solution for BAC detection and localization, achieving .98 AUC, 94% sensitivity, and 96% specificity across both FFDM and DBT mammograms. The company also markets cmTriage (FDA-cleared 2019, K183285) for mammography workflow optimization and is developing cmAssist (cancer detection with region-of-interest highlighting) and cmDensity (automated BI-RADS breast density classification).
CureMetrix generates revenue through subscription-based SaaS licensing of its FDA-cleared SaMD products to healthcare providers and imaging centers, deployed via direct enterprise sales supported by a National Account Team that provides personalized demos, ground-truth studies, IRB protocol support, and data-sharing initiatives. Products are distributed through direct enterprise sales as well as through integration partnerships with Microsoft Precision Imaging Network, CARPL.ai, Ferrum Health, Covera Health, Therapixel, and other radiology AI platforms, with deployment at over 400 clinical sites including enterprise customers such as Northwell Health and Rezolut Imaging.
The company holds a multi-jurisdictional regulatory footprint spanning FDA clearance in the US, ANVISA registration in Brazil, MDSAP certification, ISO 13485, and ISO 27001, and has been the subject of a $307 million acquisition announcement by Stryker to bolster its AI-enabled imaging capabilities for robotic-assisted care pathways.
CureMetrix firmographics
Firmographics- Name
- CureMetrix
- Legal name
- CureMetrix, Inc.
- Website
- https://curemetrix.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CureMetrix develops FDA-cleared AI software for mammography analysis, detecting breast arterial calcifications and cardiovascular risk on routine screening mammograms for healthcare providers and imaging centers, deployed at 400+ clinical sites.
- Ownership category
- akta.pro rank
CureMetrix industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Breast Imaging Centers (Mammography/Tomosynthesis) (HLAFAKAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where CureMetrix is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CureMetrix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- FDA-cleared SaMD Software Licensing: SaaS-based deployment of AI-powered medical device software within licensed healthcare provider and imaging facility environments. Products require separate agreements for access and use.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CureMetrix product offering
Product offeringCore offering
CureMetrix develops and sells FDA-cleared AI-powered Software as a Medical Device (SaMD) for mammography analysis. Its flagship product cmAngio detects and localizes Breast Arterial Calcifications (BAC) on routine screening mammograms, transforming standard breast cancer screening into a dual-purpose exam that simultaneously surfaces cardiovascular risk. The portfolio includes cmAngio, cmTriage (workflow optimization), cmAssist (cancer detection scoring), and cmDensity (breast density analysis).
Product overview
CureMetrix develops a suite of FDA-cleared AI-powered SaMD (Software as a Medical Device) products for mammography analysis. The portfolio consists of four products: cmAngio (FDA-cleared October 2023) for breast arterial calcification detection and localization; cmTriage (FDA-cleared) for mammography workflow optimization; cmAssist (in development) for cancer detection scoring with AI-powered region-of-interest highlighting; and cmDensity (in development) for automated breast density classification. cmAngio is the lead product and first FDA-cleared AI solution for BAC detection, achieving .98 AUC performance. The products are designed for deployment within licensed healthcare provider and imaging facility environments, with PACS integration capabilities. Regulatory status includes FDA clearance in the US and ANVISA registration in Brazil, with global expansion in progress targeting Canada, Australia, EU, and other markets.
Differentiator
Problem solved
Functional benefit
Brands
- cmAngio: FDA-cleared AI-powered breast arterial calcification (BAC) detection and localization solution for mammography.
- cmTriage
- cmAssist
- cmDensity
Products and services
- cmAngio FDA-cleared AI-powered platform for quantitative Breast Arterial Calcification (BAC) detection and localization on routine screening mammograms. Analyzes both FFDM and DBT mammograms, generates a cmAngio Scorecard, and delivers results in minutes with .98 AUC accuracy. Deployed at 400+ clinical sites. Designed for radiologists, mammography centers, and health systems.
- cmTriage FDA-cleared AI tool for mammography workflow optimization. Prioritizes mammography cases, flagging suspicious findings for immediate radiologist review and reducing turnaround time for critical cases. Works across all breast densities with PACS integration. Designed for radiology practices and imaging centers.
- cmAssist AI-powered mammography decision support providing lesion localization, bounding, and classification of anomalies as suspicious or verifiable benign, with confidence scores. Commercially available in Brazil (ANVISA-cleared); in development in the US. Designed for radiologists performing breast cancer screening.
Quantifiable outcome
- 3× higher mortality rate in women with BAC (7.8% vs 2.3%)
- +4 more outcomes
Companies that use CureMetrix
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
CureMetrix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability6 records
Feature4 records
CureMetrix partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Rezolut ImagingcoreAgreement to implement cmAngio software across Rezolut's imaging network, enabling detection of breast arterial calcifications on routine mammograms alongside breast cancer screening. Deployment began January 23rd, 2026.
- TherapixelcorePartnership to integrate CureMetrix's cmAngio (FDA-cleared BAC detection) with Therapixel's MammoScreen (breast cancer detection AI) into a unified platform enabling radiologists to screen for both breast cancer and breast arterial calcifications through a single installation.
- American Heart Association Center for Health Technology & InnovationcoreCureMetrix joined the AHA Center for Health Technology & Innovation's Innovators' Network, contributing AI-driven solutions including FDA-cleared cmAngio software for BAC detection and collaborating on clinical outcome studies to develop digital health solutions and improve healthcare outcomes.
- Microsoft PIN (Precision Imaging Network)corePart of Microsoft Health Solutions Radiology Workflow portfolio, the Precision Imaging Network connects AI developers with healthcare providers to deliver advanced imaging intelligence at scale.
- ExscientiaminorCollaboration announced in June 2024 between Exscientia and CureMetrix for AI-driven drug R&D applications.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
CureMetrix competitors and assessment
Company assessmentEmerging players
- Aidence: European radiology AI company focused on lung and other oncology imaging AI. Emerging player in clinical AI that competes for the same hospital AI deployment budgets and PACS integration points as CureMetrix.
Direct peers
- Volpara Health: Breast density and risk assessment software provider used by imaging centers worldwide. Direct competitor in automated breast density analysis (cmDensity's category) and mammography reporting workflow tools.
- Densitas: AI breast density and mammography quality analytics company. Direct peer competing specifically in automated breast density assessment (cmDensity) and mammography reporting workflows.
- Lunit: South Korean medical imaging AI company providing breast and chest X-ray AI solutions, deployed in 3,000+ hospitals globally. Direct peer in mammography AI and named integration partner via the Microsoft Precision Imaging Network.
- iCAD: Specialist in breast health AI and analytics, including ProFound AI for breast cancer detection and breast density assessment. Direct competitor in mammography AI decision support and density classification.
- Therapixel: French AI mammography company whose MammoScreen product detects breast cancer on screening mammograms. Direct peer to CureMetrix in mammography AI; CureMetrix and Therapixel announced a partnership in Dec 2025 to integrate cmAngio (BAC) with MammoScreen (cancer detection) into a unified platform.
- DeepHealth (RadNet subsidiary): AI radiology company acquired by RadNet that offers breast cancer detection and workflow AI integrated across a large imaging network. Direct peer in mammography AI with vertical integration advantages via RadNet's imaging centers.
Broad incumbents
- Hologic: Dominant mammography equipment manufacturer (3Dimensions, Genius AI) with bundled AI capabilities across breast imaging. Broad incumbent that competes via integrated hardware-software offerings in the same radiology customer base.
- GE HealthCare: Global medical imaging OEM with mammography systems (Pristina) and AI-enabled radiology workflow offerings. Broad incumbent competing through hardware-software bundling across the same imaging center customer base.
- Siemens Healthineers: Major imaging OEM with mammography systems (MAMMOMAT) and AI-augmented radiology portfolio. Broad incumbent overlapping with CureMetrix's hospital and imaging center customers.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
CureMetrix social profiles
Digital presenceCureMetrix compliance and trust
Trust signalCompliance6 records
CureMetrix financial estimates
Financial estimateRevenue estimate
Valuation estimate
CureMetrix leadership team
Management profileNumber of profiles
Profiles6 records
CureMetrix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CureMetrix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CureMetrix
What does CureMetrix do?
CureMetrix develops and sells FDA-cleared AI-powered Software as a Medical Device (SaMD) for mammography analysis. Its flagship product cmAngio detects and localizes Breast Arterial Calcifications (BAC) on routine screening mammograms, transforming standard breast cancer screening into a dual-purpose exam that simultaneously surfaces cardiovascular risk. The portfolio includes cmAngio, cmTriage (workflow optimization), cmAssist (cancer detection scoring), and cmDensity (breast density analysis).
Is CureMetrix a public or private company?
CureMetrix is a private company. It is classified as venture growth investor backed and is currently operating.
When was CureMetrix founded?
CureMetrix was founded in 2014. It employs 11 to 50 people.
Where is CureMetrix based?
CureMetrix is headquartered in San Diego, United States, in the North America region.
How does CureMetrix make money?
One revenue line is on record: FDA-cleared SaMD Software Licensing.
Who are CureMetrix's main competitors?
Aidence is listed as an emerging player. Direct peers are Volpara Health, Densitas, Lunit, iCAD, Therapixel and DeepHealth (RadNet subsidiary). Broad incumbents are Hologic, GE HealthCare and Siemens Healthineers.
Does CureMetrix have an API?
No public API is recorded for CureMetrix.
What industry is CureMetrix in?
CureMetrix's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAFAKAD, Breast Imaging Centers (Mammography/Tomosynthesis). Its NAICS code is 3391 and its SIC code is 3841.